Albumedix to acquire Supermin albumin variant assets of Eleven Biotherapeutics - MarketLine Financial Deals

Albumedix to acquire Supermin albumin variant assets of Eleven Biotherapeutics

Albumedix to acquire Supermin albumin variant assets of Eleven Biotherapeutics - MarketLine Financial Deals
Albumedix to acquire Supermin albumin variant assets of Eleven Biotherapeutics
Published Jan 26, 2016
2 pages — Published Jan 26, 2016
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Albumedix A/S, a Denmark-based albumin engineering and protein manufacturing company, has entered into an agreement to acquire the Supermin albumin variant assets of Eleven Biotherapeutics, Inc.

  
Source:
Document ID
MA164319_160129
Country
Country
Ticker
EBIO=US
Ticker
NZYM B=DK
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Albumedix to acquire Supermin albumin variant assets of Eleven Biotherapeutics" Jan 26, 2016. Alacra Store. Dec 06, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Albumedix-to-acquire-Supermin-albumin-variant-assets-of-Eleven-Biotherapeutics-2052-117707>
  
APA:
MarketLine Financial Deals. (2016). Albumedix to acquire Supermin albumin variant assets of Eleven Biotherapeutics Jan 26, 2016. New York, NY: Alacra Store. Retrieved Dec 06, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Albumedix-to-acquire-Supermin-albumin-variant-assets-of-Eleven-Biotherapeutics-2052-117707>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.